Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.
Mitoxantrone-induced suicidal erythrocyte death.
Roche reports positive studies of MabThera given by subcutaneous injection
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
National Cancer Institute Search for Clinical Trials
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Signal Transduction in the Blood-Brain Barriers
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Prospective memory, emotional valence, and multiple sclerosis.
Refining diagnosis of multiple sclerosis with revised MRI criteria.
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study.
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
FDA denies Teva Copaxone generic trials petition
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Uhthoff's phenomena in MS-clinical features and pathophysiology.

Pages